---
type: "Nootropic"
title: "CDP-Choline"
description: "CDP-choline is a choline and nucleotide precursor. It has been examined in some memory studies; dopamine receptor findings are animal data and do not establish improved motivation in healthy people."
resource: "https://nootropikler.com/nootropics/cdp-choline"
tags: ["citicoline", "choline"]
timestamp: 2026-11-11T00:00:00Z
category: "cognitive"
source: "semi-synthetic"
latin: "Sitidin 5'-difosfokolin"
language: "en"
---

# CDP-Choline

*Sitidin 5'-difosfokolin*

CDP-choline is a choline and nucleotide precursor. It has been examined in some memory studies; dopamine receptor findings are animal data and do not establish improved motivation in healthy people.

## Quick profile

| Property | Value |
| --- | --- |
| Onset of Effect | No established timeframe |
| Dose used in research | Depends on the studied product and protocol |
| Safety | See detailed safety warnings |

> Correction · 2026-11-11. ICTUS, radiolabelled pharmacokinetics and the EFSA assessment were separated. The general dose and half-life curve, unproven mechanisms and dose-reduction advice were removed.

## What is CDP-Choline?

CDP-choline is a choline and nucleotide precursor. It has been examined in some memory studies; dopamine receptor findings are animal data and do not establish improved motivation in healthy people.

## Mechanism of Effect

Dinsdale et al. (1983) reported two plasma-radioactivity peaks at 1 and 24 hours after 300 mg radiolabelled citicoline in 6 healthy adults. Respiratory and urinary elimination were biphasic.

Elimination of radioactivity and metabolites is not the plasma half-life of unchanged citicoline. This small study does not validate a one-compartment decay curve or personal intake times.

## Clinical Evidence

ICTUS (2012) compared citicoline with placebo in 2298 people with moderate-to-severe acute ischemic stroke. Global recovery at day 90 after six weeks of treatment was similar (OR 1.03; 95% CI 0.86–1.25); the trial stopped for futility.

This hospital trial did not study memory enhancement in healthy people. Similar adverse-event rates do not establish long-term or combination safety. Funding came from Ferrer Grupo.

EFSA (2024) concluded that a cause-and-effect relationship was not established between citicoline and improvement, maintenance or reduced loss of memory in middle-aged and older adults with age-associated subjective memory complaints.

The single positive 12-week trial at 500 mg/day was not corroborated by other data; convincing human-mechanism evidence was not supplied. This health-claim assessment is not product safety approval.

## Dose information and research limits

> **Dose information and research limits:** This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

## Safety and Side Effects

These sources do not determine long-term or combination safety of CDP-choline in healthy people. Similar adverse-event rates in a stroke trial are not general safety approval.


## Frequently Asked Questions

### What does CDP-Choline do?

CDP-choline is a choline and nucleotide precursor. It has been examined in some memory studies; dopamine receptor findings are animal data and do not establish improved motivation in healthy people.

### What is the recommended dosage for CDP-Choline?

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

### What are the side effects of CDP-Choline?

These sources do not determine long-term or combination safety of CDP-choline in healthy people. Similar adverse-event rates in a stroke trial are not general safety approval.

### Is CDP-Choline legal in Türkiye and where can it be obtained?

Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.

### When does the effect of CDP-Choline begin and for how long should it be used?

No established timeframe

## Sources

- Secades JJ. (2011). Citicoline: pharmacological and clinical review, 2010 update. *Revista de Neurología*, 52(Suppl 2), S1–S62. [PubMed · PMID 21432836](https://pubmed.ncbi.nlm.nih.gov/21432836/)
- Alvarez-Sabín J, Román GC. (2013). The role of citicoline in neuroprotection and neurorepair in ischemic stroke. *Brain Sciences*, 3(3), 1395–1414. [PubMed · PMID 24961534](https://pubmed.ncbi.nlm.nih.gov/24961534/)
- Dávalos A, et al. (2012). Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). *The Lancet*, 380(9839), 349–357. [PubMed · PMID 22691567](https://pubmed.ncbi.nlm.nih.gov/22691567/)
- Fioravanti M, Buckley AE. (2006). Citicoline (Cognizin) in the treatment of cognitive impairment. *Clinical Interventions in Aging*, 1(3), 247–251. [PubMed · PMID 18046877](https://pubmed.ncbi.nlm.nih.gov/18046877/)
- Dinsdale JR, et al. (1983). Pharmacokinetics of 14C CDP-choline. *Arzneimittel-Forschung*, 33(7A), 1066–1070. [PubMed · PMID 6412727](https://pubmed.ncbi.nlm.nih.gov/6412727/)
- EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). (2024). Citicoline and support of the memory function: Evaluation of a health claim. https://www.efsa.europa.eu/en/efsajournal/pub/8861 [European Food Safety Authority](https://www.efsa.europa.eu/en/efsajournal/pub/8861)

## Related nootropics

- [Alpha-GPC](/okf/nootropics/alpha-gpc.md)
- [Lion's Mane](/okf/nootropics/lions-mane.md)
- [Bacopa Monnieri](/okf/nootropics/bacopa-monnieri.md)
